A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

By J. Fueyo, C. Gomez-Manzano, R. Alemany, Polly S.Y. Lee, Timothy J Mcdonnell, P. Mitlianga, Yue-Xi Shi, V. Levin, W. A. Yung, A. Kyritsis. Oncogene, 2000

820 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/ecce618b2f6a52b466aecfd8ef82e847b92f29ba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. F. McCormick
2. C. Sherr
3. J. Campisi
4. R. Weinberg
5. Annapoorni Rangarajan

In Oncology

1. F. McCormick
2. C. Sherr
3. R. Weinberg
4. J. Campisi
5. Annapoorni Rangarajan

Citations in the corpus

• Oncolytic viruses: a new class of immunotherapy drugs (2015, methodology): “Parvovirus H-1PV has been used in clinical trials of glioblastoma multiforme (GBM) 33 likely to be permissive to infection 31, 36, 37 .”
• The RB and p53 pathways in cancer. (2002, background): “An adenovirus expressing a mutant form of E1A that cannot bind RB should replicate selectively and kill cells lacking functional RB (Fueyo et al., 2000).”